NCT06992674View on ClinicalTrials.gov

The R-E-V-I-V-A-L Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

December 1, 2026

Conditions
Vestibular Migraine
Interventions
DRUG

Rimegepant

Take 75mg qd of oral sulfate remigipan orally disintegrating tablets

DRUG

Placebo

Take 75mg qd of placebo

Trial Locations (1)

310000

Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88 Jiefang Road, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06992674 - The R-E-V-I-V-A-L Study | Biotech Hunter | Biotech Hunter